The two-armed, randomized clinical trial has enrolled 200 patients at sites in the Philippines, Korea, India, Malaysia, Thailand, Hong Kong, Singapore, Serbia, Poland, Croatia, and Italy.
The primary endpoint of the clinical trial is to assess the survival of patients receiving Light Infusion Therapy (Litx) versus those receiving standard-of-care therapies.
Llew Keltner, president and CEO of Light Sciences Oncology, said: “We are pleased to have enrolled the final patient in this pivotal clinical trial of Litx in primary liver cancer.
“We look forward to seeing a statistically significant survival benefit of Litx and proceeding with a new drug application to the FDA, European Medicines Agency, and other regulatory authorities in 2009.”